Approval · Notice of Compliance 13914 · 2012
ATOMOXETINE: Notice of Compliance 13914
Issued November 28, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13914
- Date
- November 28, 2012
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Selective norepinephrine reuptake inhibitor for attention deficit hyperactivity disorder (adhd)
- Canadian reference product
- STRATTERA (Eli Lilly Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATOMOXETINE | 02396904 | Marketed |
| ATOMOXETINE | 02396912 | Marketed |
| ATOMOXETINE | 02396920 | Marketed |
| ATOMOXETINE | 02396939 | Marketed |
| ATOMOXETINE | 02396947 | Marketed |
Medicinal ingredients
- ATOMOXETINE HYDROCHLORIDE 10 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 18 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 25 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 40 MG per CAP
- ATOMOXETINE HYDROCHLORIDE 60 MG per CAP